Pfizer Inc. and OPKO Health Inc.'s medicine somatrogon increased the height of minors with growth hormone deficiency as effectively as Pfizer's other therapy Genotropin.
Somatrogon was investigated in a phase 3 clinical trial of 224 prepubescent patients with growth hormone deficiency, or GHD. This condition affects one in about 4,000 to 10,000 people, causing short height. GHD can occur at the time of birth or develop later in life because of genetics, trauma, infections or radiation therapy.
The patients received either a dose of somatrogon once every week for 12 months, or an injection of Genotropin, also known as somatropin, each day.
The Pfizer-Opko drug increased minors' height as effectively as somatropin, meeting the main goal of the study. The somatrogon group also had a more significant change in height from the start of the study to the six month point and at the end of the study.
Pfizer and Opko entered into an agreement in 2014 to develop and commercialize somatrogon to treat GHD. Opko Health is overseeing the clinical development of the drug and Pfizer the commercialization.
Further analysis of the data is ongoing and final study results will be presented at a future scientific meeting, Opko Health said in an Oct. 21 press release.